Forbes

A public health expert explains how GLP-1 drugs could change the landscape of healthcare and public health in the future.

Chocolate poisoning can lead to costly vet bills, while costumes, decorations and open doors pose other risks. Here's how to protect your pets this Halloween.

Alignment Healthcare swung to an $8 million loss as the industrywide struggle grappling with costs of care for older adults in Medicare Advantage plans lingers.

Two neurologists explain the progress and the barriers keeping patients from timely care for mild cognitive impairment and early Alzheimer's.

Bird flu is uncontrolled on a mink farm in Utah, threatening spillover into humans. Congress seems focused on buoying the mink industry and has not addressed the threat.

Holmes played a key role in staging the now iconic shot. In “You Can See Everything,” she claims to hate it now. But does she really?

A 'Human in the Loop' in the healthcare in the AI Era has many , functions- the one of communicator, navigator and empath is key.

Two-time Olympic gold medalist snowboarder Chloe Kim discusses how her recent diagnosis with attention-deficit hyperactivity disorder took a while and her ADHD treatment

Health insurance premiums are rising in 2027. Discover six ways to lower costs, compare coverage and save on medical care without taking unnecessary risks.

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.

A doctor writes a guide to the seven health issues voters care about most in the 2026 midterms, from health costs and ACA premiums to Medicaid, fraud and abortion.

At Health Datapalooza, patient advocates explore how healthcare can move beyond a seat at the table to recognize expertise and give patients meaningful influence.

Mike Collette’s CFO said PatientPoint was three weeks from shutdown. Here’s how he built a point-of-care giant and later bought the rival that fooled investors.